Despite 15 years of experience with tumor necrosis factor -α inhibitor (TNFI) -induced psoriasis, our understanding of its pathogenesis remains incomplete. A recent case-control study identified risk factors and triggers associated with the onset of this condition.
Co-management clinics yield improved patient outcomes and increased opportunities for research and education. In this article, rheumatologist Elaine Husni, MD, MPH, and dermatologist Anthony Fernandez, MD, PhD, discuss their new shared clinic.
Is it idiopathic psoriasis or TNFi-induced psoriasis? A new study finds histological differences between these two types of psoriatic lesions that impact treatment.
Comanagement of TNFI-induced psoriasis in rheumatology and dermatology means better patient outcomes, according to a decade of experience at Cleveland Clinic.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
This is the first reported case in which an HIV-positive patient with both severe psoriasis and KS is treated with ustekinumab. The results suggest that the biologic may be a safe and effective treatment for these patients.
A recent Cleveland Clinic study determined that paraoxonase-1 (PON1) has the potential for use as a biomarker for cardiac risk in psoriatic disease.
The Husni research lab combines clinical savvy with biochemical and molecular biology expertise to home in on the molecular basis of immune-mediated diseases. An early focus: selective TNF-α receptor inhibition.